

# Ningetinib Tosylate

Catalog No: tcsc0027426



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1394820-77-9

**Formula:**

$C_{38}H_{37}FN_4O_8S$

**Pathway:**

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

**Target:**

c-Met/HGFR;VEGFR;TAM Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 8.25 mg/mL (11.32 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**


728.79

## Product Description

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC<sub>50</sub>**s of 6.7, 1.9 and c-Met, **VEGFR2** and **Axl**, respectively.

**In Vitro:** Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC<sub>50</sub>s of 6.7, 1.9 and 50 values of 8.6 and 6.3 nM, respectively<sup>[1]</sup>.

**In Vivo:** When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib Tosylate (CT053PTSA) potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues. In orthotopic U87MG human glioblastoma xenograft model, Ningetinib Tosylate prolongs the median survival time (MST) and yields significant increase in life-span value (ILS=32%, p=0.003) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!